about
Fatty acids as therapeutic auxiliaries for oral and parenteral formulationsCombinatorial peptide libraries: mining for cell-binding peptides.Ex-vivo evaluation of alginate microparticles for Polymyxin B oral administration.Intranasal M cell uptake of nanoparticles is independently influenced by targeting ligands and buffer ionic strength.Polymeric nanoparticle technologies for oral drug delivery.Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticlesUnique insights into the intestinal absorption, transit, and subsequent biodistribution of polymer-derived microspheresFormulation and optimization of itraconazole polymeric lipid hybrid nanoparticles (Lipomer) using Box Behnken design.Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile saltGene transfer approaches for the treatment of inflammatory bowel disease.Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes.Oral delivery of pathogens from the intestine to the nervous system.Improving M cell mediated transport across mucosal barriers: do certain bacteria hold the keys?Pollen grains for oral vaccinationParticle uptake by Peyer's patches: a pathway for drug and vaccine delivery.Starch microparticles as vaccine adjuvant.Polymeric nanoparticle drug delivery technologies for oral delivery applications.Chitosan nanoparticles for oral drug and gene delivery.M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis.Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.Nanoparticles for transcutaneous vaccination.Engineering strategies to enhance nanoparticle-mediated oral delivery.Fabrication and in vitro/in vivo evaluation of amorphous andrographolide nanosuspensions stabilized by d-α-tocopheryl polyethylene glycol 1000 succinate/sodium lauryl sulfateBioadhesive delivery systems for mucosal vaccine delivery.Topical and mucosal liposomes for vaccine delivery.Nanomaterials for enhanced immunity as an innovative paradigm in nanomedicine.Biological voyage of solid lipid nanoparticles: a proficient carrier in nanomedicine.Mucosal vaccine delivery: Current state and a pediatric perspectivePolymer-lipid hybrid systems: merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery.pH responsive cylindrical MSN for oral delivery of insulin-design, fabrication and evaluation.Effects of food-borne nanomaterials on gastrointestinal tissues and microbiota.Surface-modified P(HEMA-co-MAA) nanogel carriers for oral vaccine delivery: design, characterization, and in vitro targeting evaluation.In vitro and ex vivo characterization of lectin-labeled Mycobacterium tuberculosis antigen-containing microspheres for enhanced oral delivery.Electrostatic properties of confluent Caco-2 cell layer correlates to their microvilli growth and determines underlying transcellular flow.Oral microparticulate vaccine for melanoma using M-cell targeting.Microfabrication for Drug DeliveryMucosal Adjuvant Potential of Quillaja saponins and Cross-linked Dextran Microspheres, Co-administered with Liposomes Encapsulated with Tetanus Toxoid.Fabrication and characterization of DNA-loaded zein nanospheres.Freeze-dried targeted mannosylated selenium-loaded nanoliposomes: development and evaluation.Enhanced anticancer activity and oral bioavailability of ellagic acid through encapsulation in biodegradable polymeric nanoparticles.
P2860
Q26828805-8C84CF3E-94F3-4E53-A13D-9BF331922A43Q31144876-F56CED15-64C1-4A59-AE4B-C5E1F96D1987Q33262949-1B12837A-3386-4317-9B46-4F66E8A8F153Q34025399-BD8CD515-B1FC-44BB-97A8-F7EE606CE4FFQ34225096-EB007559-77C9-4BBE-9CFA-19E8CE678DC8Q34661842-F4B24286-776D-4B2B-BB8E-4B16B8AC5507Q34901313-4F7B75BF-CC3A-4A64-8FCF-EA6E7E358E3BQ35033387-145BBA24-406B-4891-8AD4-F0DAE5B6E9ACQ35071614-7F62BDD9-9622-4F3A-A378-939745F3BEABQ35122162-4B1E6201-93B2-4766-8908-CE761A6FBFFBQ35287340-8F8C129F-8C81-49C7-BD0D-2D9C15A09210Q35809225-3F2EFB75-4275-4049-BA59-139D10C3478AQ35863373-4F051D8E-00FA-4BE5-9DCD-F67E951C6E16Q36100539-6F49B8F3-6412-467C-ADEB-B36624D7C1BEQ36316646-DDC5332A-9A62-4650-A4E1-06B2FCEE144BQ36316814-980D690D-09CA-4672-90BE-05FEC37B5A08Q36808308-14FCD9A8-299C-4741-A501-B67A6FA95E17Q36920450-A4E12FD6-0A4E-4397-A566-817FD97E0D90Q37032884-70D7AF4E-2320-42A7-9AEF-6ABA19972C2EQ37153923-5AEEAD10-80A5-4002-A451-B190E0CFBFF1Q37274692-4CDC3818-9D02-4261-B046-340C54688330Q37328673-6076DF91-7E56-40F6-84CB-2DF7AD80974EQ37638743-247D0433-E172-440C-84A2-7751040E514CQ37805519-B7E4DF71-4AF4-453E-B7C5-D9784E175EE4Q37848296-5AE09FCC-FCE6-469E-A827-D9B753526010Q38418305-E18F30B8-AC89-4200-8E15-41E9FB8B0DBCQ38558905-C3DE51FA-6898-4DFB-87FA-45DCDEDDF869Q38727453-F76AFACF-6C91-4D0E-A799-5EDC114488A3Q38729314-9376C48C-D184-47DA-B310-168D91BE382FQ38740986-B6DD05D2-37DA-4E3A-BC6A-FD95F672B305Q38761757-01A22677-E113-4698-B9C1-AEF6D46339F6Q38982074-32CA2913-3F9F-47B0-A364-6F1C7A890695Q39103503-6754064F-0935-4E78-89F5-83D03594A42CQ39161552-8BB28BDE-7EE1-49E0-B1C1-5B8FD091C939Q39461635-BCFE5FC2-2B08-43CC-BED3-4588C4974EAAQ41006286-DB3498AE-DC70-436E-9E45-DA1E390BFEABQ41884496-834A326C-C532-479E-8953-933C1D7A4ACAQ42415385-5C3074EF-2C90-4809-B786-D89712B64FFEQ42574200-DD2114E5-6978-4FBC-8879-79160A8DD858Q42688385-DB29E675-62DB-4E1E-B67D-F7156525BB33
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Exploiting M cells for drug and vaccine delivery.
@ast
Exploiting M cells for drug and vaccine delivery.
@en
Exploiting M cells for drug and vaccine delivery.
@nl
type
label
Exploiting M cells for drug and vaccine delivery.
@ast
Exploiting M cells for drug and vaccine delivery.
@en
Exploiting M cells for drug and vaccine delivery.
@nl
prefLabel
Exploiting M cells for drug and vaccine delivery.
@ast
Exploiting M cells for drug and vaccine delivery.
@en
Exploiting M cells for drug and vaccine delivery.
@nl
P2093
P1476
Exploiting M cells for drug and vaccine delivery.
@en
P2093
P304
P356
10.1016/S0169-409X(01)00149-1
P407
P577
2001-08-01T00:00:00Z